Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
The New England Journal of Medicine
|
September 1, 2025
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
Diabetes Care
|
April 14, 2026
Bivalent RSV Prefusion F Protein-Based Vaccine Effectiveness in Individuals With and Without Diabetes: A Prespecified Analysis of the DAN-RSV Trial
Manan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
JAMA
|
August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
European Journal of Preventive Cardiology
|
April 30, 2026
Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trial
Lisa Steen Duus, Mats C H Lassen, Niklas D Johansen, et al.
Journal of the American College of Cardiology
|
November 26, 2025
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Atrial Fibrillation: A Prespecified Analysis of the DANFLU-2 Trial
Caroline Espersen, Niklas Dyrby Johansen, Daniel Modin, et al.
European Journal of Preventive Cardiology
|
June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial
Caroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
JAMA Network Open
|
August 30, 2025
Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine: A Prespecified Secondary Analysis of the Randomized DANFLU-2 Trial
Manan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
JAMA Cardiology
|
August 30, 2025
High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial
Niklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
European Heart Journal
|
August 30, 2025
High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial
Manan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
The New England Journal of Medicine
|
September 1, 2025
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults
Niklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
The New England Journal of Medicine
|
September 1, 2025
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
Diabetes Care
|
April 14, 2026
Bivalent RSV Prefusion F Protein-Based Vaccine Effectiveness in Individuals With and Without Diabetes: A Prespecified Analysis of the DAN-RSV Trial
Manan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
JAMA
|
August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
European Journal of Preventive Cardiology
|
April 30, 2026
Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trial
Lisa Steen Duus, Mats C H Lassen, Niklas D Johansen, et al.
Journal of the American College of Cardiology
|
November 26, 2025
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Atrial Fibrillation: A Prespecified Analysis of the DANFLU-2 Trial
Caroline Espersen, Niklas Dyrby Johansen, Daniel Modin, et al.
European Journal of Preventive Cardiology
|
June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial
Caroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
JAMA Network Open
|
August 30, 2025
Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine: A Prespecified Secondary Analysis of the Randomized DANFLU-2 Trial
Manan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
JAMA Cardiology
|
August 30, 2025
High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial
Niklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
European Heart Journal
|
August 30, 2025
High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial
Manan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
The New England Journal of Medicine
|
September 1, 2025
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults
Niklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
Page
of 5